<DOC>
	<DOCNO>NCT00942708</DOCNO>
	<brief_summary>This study evaluate safety , tolerability efficacy open-label fluoxetine three month among patient pulmonary arterial hypertension .</brief_summary>
	<brief_title>Safety Efficacy Fluoxetine Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>Idiopathic pulmonary arterial hypertension ( PAH ) life-threatening disorder uncertain cause lead progressive right heart failure death . Average survival improve 2.8 year early 1990s approximately 5-7 year current treatment , patient still die disease . Two class oral medication approve use PAH : endothelin-1 antagonist , phosphodiesterase-5 inhibitor . Both improve walk distance symptom PAH , patient still continue dyspnea , fatigue significant elevation pulmonary pressure . Those remain severely impaired generally start continuous intravenous prostacyclin . For less ill still symptomatic , option available . Primary endpoint : primary endpoint change pulmonary vascular resistance ( PVR ) measure right heart catheterization three month therapy . Secondary endpoint Efficacy : - Other three month catheterization variable : right atrial pressure , pulmonary arterial pressure , Fick cardiac output , pulmonary arterial oxygen saturation , pulmonary capillary wedge pressure - Six minute walk distance - WHO functional class - Brain natriuretic peptide Safety tolerability endpoint include change baseline three month QIDS-SR depression scale , systolic diastolic blood pressure ( systemic ) tabulation adverse event include limit : - Death - Hospitalization - Symptomatic hypotension - Gastrointestinal side effect - Depression</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>1 . Signed informed consent prior studymandated procedure 2 . PAH follow subtypes : idiopathic PAH WHO functional class IIIII 3 . Catheterization within one week show mPAP &gt; =25 , wedge LV end diastolic pressure â‰¤15 , PVR &gt; 4 wood unit , baseline fick cardiac output result available 4 . Age 1675 5 . Able complete six minute walk distance 6 . Women childbearing potential* : negative serum pretreatment pregnancy test + consistently correctly use reliable method contraception** Oral approve PAH therapy &gt; 3 month change dose &gt; 1 month 1 . PAH connective tissue disease , congenital heart disease , portal hypertension , glycogen storage disease , Gaucher 's disease , hereditary hemorrhagic telangiectasia , hemoglobinopathy , myeloproliferative disorder . 2 . Moderate severe obstructive restrictive lung disease : forced expiratory volume 1 second/forced vital capacity ( FEV1/FVC ) &lt; 70 % FEV1 &lt; 60 % predict value bronchodilator administration . total lung capacity ( TLC ) &lt; 60 % predict . 3 . Systemic systolic blood pressure &lt; 100 mmHg Breastfeeding 4 . Significant liver , renal medical disease prevent completion study procedures life expectancy &lt; 12 month , acute chronic physical impairment ( dyspnea ) , limit ability comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Pulmonary Hypertension</keyword>
</DOC>